A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Trial Details

NCT ID
NCT07365319
Phase
PHASE2 / PHASE3
Sponsor
Eikon Therapeutics
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • EIK1001
  • Pembrolizumab (KEYTRUDA®)
  • Placebo
  • Paclitaxel + Carboplatin
  • Nab-paclitaxel + Carboplatin
  • Pemetrexed + Cisplatin /Carboplatin
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Glendale, California, United States|34.14251,-118.25508
  • Pueblo, Colorado, United States|38.25445,-104.60914
  • Mineola, New York, United States|40.74927,-73.64068
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participant must be ≥ 18 years old at the time of signing the informed consent.
  • Participant has a life expectancy of at least 3 months.
  • Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for s…
  • Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →